BRPI0513825A - combinações de epotilona - Google Patents

combinações de epotilona

Info

Publication number
BRPI0513825A
BRPI0513825A BRPI0513825-6A BRPI0513825A BRPI0513825A BR PI0513825 A BRPI0513825 A BR PI0513825A BR PI0513825 A BRPI0513825 A BR PI0513825A BR PI0513825 A BRPI0513825 A BR PI0513825A
Authority
BR
Brazil
Prior art keywords
combinations
epothilone
epotilone
retarding
progression
Prior art date
Application number
BRPI0513825-6A
Other languages
English (en)
Inventor
Richard Paul Becker
Anandhi Ranganathan Johri
Paul M J Mcsheehy
Sara Zaknoen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513825A publication Critical patent/BRPI0513825A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAçõES DE EPOTILONA. A invenção refere-se a combinações de (a) uma epotilona com (b) dois ou mais de outros agentes antineoplásicos para uso simultâneo, separado ou seqüencial, em particular para o retardo da progressão ou tratamento de uma doença proliferativa.
BRPI0513825-6A 2004-07-26 2005-07-25 combinações de epotilona BRPI0513825A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59122504P 2004-07-26 2004-07-26
PCT/EP2005/008076 WO2006010585A1 (en) 2004-07-26 2005-07-25 Epothilone combinations

Publications (1)

Publication Number Publication Date
BRPI0513825A true BRPI0513825A (pt) 2008-05-20

Family

ID=35058801

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513825-6A BRPI0513825A (pt) 2004-07-26 2005-07-25 combinações de epotilona

Country Status (17)

Country Link
US (1) US20090041715A1 (pt)
EP (1) EP1773334A1 (pt)
JP (1) JP2008507573A (pt)
KR (1) KR20070037498A (pt)
CN (1) CN1988904A (pt)
AU (1) AU2005266484A1 (pt)
BR (1) BRPI0513825A (pt)
CA (1) CA2573949A1 (pt)
IL (1) IL180604A0 (pt)
MA (1) MA28812B1 (pt)
MX (1) MX2007000971A (pt)
NO (1) NO20071038L (pt)
RU (1) RU2007106931A (pt)
TN (1) TNSN07025A1 (pt)
TW (1) TW200616626A (pt)
WO (1) WO2006010585A1 (pt)
ZA (1) ZA200700201B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
JP2011503075A (ja) * 2007-11-09 2011-01-27 ノバルティス アーゲー エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034437A2 (en) * 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US20090041715A1 (en) 2009-02-12
NO20071038L (no) 2007-04-26
CA2573949A1 (en) 2006-02-02
MX2007000971A (es) 2007-04-10
CN1988904A (zh) 2007-06-27
WO2006010585A1 (en) 2006-02-02
EP1773334A1 (en) 2007-04-18
TW200616626A (en) 2006-06-01
KR20070037498A (ko) 2007-04-04
IL180604A0 (en) 2008-03-20
ZA200700201B (en) 2008-02-27
JP2008507573A (ja) 2008-03-13
TNSN07025A1 (en) 2008-06-02
AU2005266484A1 (en) 2006-02-02
MA28812B1 (fr) 2007-08-01
RU2007106931A (ru) 2008-09-10

Similar Documents

Publication Publication Date Title
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0618473A2 (pt) combinações e métodos de uso de um oligodeoxinucleotìdeo imunomodulador
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
EA200701918A1 (ru) Белок липокалин
HN2005029978A (es) Formulaciones
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
EA200900767A1 (ru) Антагонистические антитела против ephb3
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
UY28344A1 (es) Nuevos compuestos
TNSN07025A1 (en) Epothilone combinations
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
BRPI0820832A2 (pt) Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica.
DK1861080T3 (da) Idebenon til behandling af muskeldystrofier
UY29417A1 (es) Agentes endoparasiticidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.